ProMIS Neurosciences Shares Rise on Positive Interim Trial Data for Alzheimer’s Drug
ProMIS Neurosciences (PMN:NASDAQ) saw a rise in share price after releasing interim data from an early-stage trial of its lead drug candidate, PMN310. The Canadian biotech company reported six-month blinded results showing positive outcomes in patients with Alzheimer's disease. Based on the findings, Guggenheim upgraded its outlook and raised its price target for ProMIS. The Phase 2 clinical data demonstrated that PMN310 showed signs of slowing cognitive decline among participants. This development has generated optimism about the drug’s potential to address a significant unmet medical need in Alzheimer's treatment. The market response was positive, with investors reacting favorably to both the trial results and analyst upgrades. The news highlights growing interest in novel therapies for neurodegenerative diseases and could position ProMIS as a key player in this competitive space.
Topics: Alzheimer's biotech stock movement